Galectin Therapeutics Inc GALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans
Galectin Shares Fall After FDA Raises Issues With Belapectin Program
Trading Information
- Previous Close Price
- $2.99
- Day Range
- $2.90–3.18
- 52-Week Range
- $2.03–7.13
- Bid/Ask
- $2.50 / $3.19
- Shares Outstanding
- 100.85M
- Market Cap
- $316.67M
- Volume/Avg
- 223,443 / 276,201
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Valuation
Metric | GALT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | GALT |
|---|---|
Quick Ratio | 0.09 |
Current Ratio | 0.10 |
Interest Coverage | −2.61 |
Quick Ratio
GALT
Profitability
Metric | GALT |
|---|---|
Return on Assets (Normalized) | −133.00% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −464.34% |
Return on Assets
GALT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|qRs<V# | LOCK|B<rbz | $139B | |||
| Moderna Inc MRNA | LOCK|wsWrm# | LOCK|bz! | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|?GKfN^J | LOCK|VL#Q | $94B | |||
| argenx SE ADR ARGX | LOCK|^q?TJx | LOCK|vcb | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&vB@?Tc | LOCK|&%l | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|X^#@?VC& | LOCK|gJ>j | $30B | |||
| Incyte Corp INCY | LOCK|j?^^^tG | LOCK|gX$ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|?V!p?@y | LOCK|@D? | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#%wWSkm | LOCK|^T&S | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|%C?L^X | LOCK|MH | $15B |
United States